Form 8-K · Current Report · Filed 2025-05-22
Zoetis Announces Board Changes and Shareholder Proposal Results
On May 21, 2025, Zoetis Inc. announced that Mr. Robert Scully retired from the Board of Directors prior to the company's Annual Meeting, and Dr. Mark Stetter was elected to the Board. At the Annual Meeting, shareholders voted on four proposals: electing twelve directors, a non-binding advisory vote on executive compensation, ratifying the appointment of KPMG LLP as the independent registered public accounting firm, and a shareholder proposal regarding a special shareholder meeting improvement. All twelve directors were elected, the executive compensation program was approved, the appointment of KPMG LLP was ratified, and the shareholder proposal was not approved.
- Filer
- Zoetis Inc. ZTS · NYSE
- Filed
- Accession
- 0001555280-25-000213
- CIK
- 0001555280
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Submission of Matters to a Vote of Security Holders
Financial Statements and Exhibits
Market reaction
Close before filing
$161.44
Next session
+0.7%
Since filing
-52.1%
Latest close
$77.29
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ZTS reporting the same item, with the next session's move:
Exhibits (1)
About Zoetis Inc.
Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
Never miss another ZTS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.